5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 6.06▼ | 6.05▲ | 6.07▼ | 5.99▲ | 6.03▼ |
MA10 | 6.05▲ | 6.06▼ | 6.04▲ | 5.99▲ | 7.97▼ |
MA20 | 6.06▼ | 6.00▲ | 5.99▲ | 6.06▼ | 8.91▼ |
MA50 | 5.99▲ | 5.99▲ | 5.99▲ | 8.30▼ | 8.68▼ |
MA100 | 5.99▲ | 5.98▲ | 6.01▲ | 8.87▼ | 8.60▼ |
MA200 | 5.98▲ | 6.15▼ | 7.44▼ | 8.76▼ | 11.71▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.003▼ | 0.006▲ | 0.012▲ | 0.152▲ | -0.520▼ |
RSI | 52.888▲ | 53.721▲ | 54.105▲ | 35.325▼ | 33.972▼ |
STOCH | 64.372 | 60.565 | 77.776 | 47.135 | 6.688▼ |
WILL %R | -59.091 | -23.214▲ | -23.214▲ | -47.840 | -92.722▼ |
CCI | -19.608 | 34.006 | 51.852 | 46.535 | -97.759 |
Tuesday, April 29, 2025 01:35 AM
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. (“Nyxoah” or the “Company”) (NASDAQ: NYXH). Such investors are ...
|
Wednesday, April 16, 2025 03:00 AM
LLC is investigating potential claims on behalf of purchasers of Nyxoah S.A. ("Nyxoah" or "the Company") (NASDAQ:NYXH). Investors who purchased Nyxoah securities are encouraged to obtain ...
|
Wednesday, April 16, 2025 01:00 AM
00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), which develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
01/05/25 | 6.15 | 6.19 | 5.985 | 6.01 | 58,891 |
30/04/25 | 5.93 | 6.20 | 5.81 | 6.14 | 68,419 |
29/04/25 | 5.87 | 5.94 | 5.85 | 5.92 | 43,709 |
28/04/25 | 5.91 | 6.17 | 5.91 | 6.01 | 70,885 |
25/04/25 | 5.86 | 6.0576 | 5.85 | 5.87 | 48,740 |
24/04/25 | 5.99 | 6.19 | 5.75 | 5.92 | 206,659 |
23/04/25 | 6.24 | 6.33 | 6.00 | 6.03 | 269,973 |
22/04/25 | 6.00 | 6.195 | 5.90 | 6.05 | 185,144 |
21/04/25 | 6.07 | 6.08 | 5.90 | 5.94 | 105,259 |
17/04/25 | 5.98 | 6.09 | 5.9005 | 6.035 | 76,631 |
|
|
||||
|
|
||||
|
|